BOSTON SCIENTIFIC CORP is expected to release its Q2 2026 10-Q filing in the upcoming earnings season. Last quarter: Boston Scientific delivered strong Q1 2026 results with revenue of $5.20B (+11.6% YoY), operating income of $1.10B (+19.5% YoY), and EPS nearly doubling to $0.90, though operating cash flow declined 35.7% to $348M.
Drawn from management commentary in the Q1 2026 10-Q:
Revenue grew 11.6% YoY to $5.20B in Q1 2026 from $4.66B in Q1 2025, reflecting continued strong demand across Boston Scientific's medical device portfolio. This growth rate outpaced cost of revenue growth of 9.4%, contributing to gross profit expansion.
Gross margin improved to 69.5% from 68.8% YoY, while operating margin expanded 140 basis points to 21.2% from 19.8%. Operating income surged 19.5% to $1.10B, demonstrating meaningful operating leverage as revenue growth outpaced expense growth.
Basic and diluted EPS both reached $0.90 in Q1 2026, compared to $0.46 and $0.45 respectively in Q1 2025, representing approximately 95-100% YoY growth. This significant jump likely reflects both improved operating performance and potential non-recurring items or tax benefits.
Revenue
$5.2B
++11.58% YoY
EPS (Basic)
$0.90
++95.65% YoY
Gross Margin
69.5%
++0.62% YoY
Operating Income
$1.1B
++19.54% YoY
Add BSX to your watchlist to get the AI analysis in your inbox within minutes of the 10-Q filing.